Acesso livre
Acesso livre

Arquivos do dia: Novembro 22, 2021

Nos EUA, FDA libera doses de reforço da vacina contra COVID-19 para adultos com mais de 18 anos – Pfizer e Moderna 6 meses depois da 2ª dose.

22 Nov, 2021 | 09:40h

United States FDA Clears COVID Vaccine Boosters for All Adults Over 18 – Pfizer & Moderna 6 Months After Second Jab – Health Policy Watch

Ver também:

FDA expands emergency authorization for Covid-19 booster shots to all adults – STAT

FDA, CDC advisors approve COVID boosters for all US adults – CIDRAP

FDA Approves Both Pfizer, Moderna Boosters for All Adults – HealthDay

Suporte respiratório não invasivo no tratamento da pneumonia aguda por COVID-19: considerações para a prática clínica e prioridades para a pesquisa – “Dois estudos randomizados e controlados indicam superioridade da ventilação não invasiva sobre o oxigênio nasal de alto fluxo na redução da necessidade de intubação.”

22 Nov, 2021 | 09:38h

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – The Lancet Respiratory Medicine

Conteúdo relacionado: [Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

 

Comentário no Twitter

 

Orientação EuGMS | Tratamento de pacientes com COVID-19 pós-aguda na reabilitação geriátrica.

22 Nov, 2021 | 09:37h

Management of post-acute COVID-19 patients in geriatric rehabilitation: EuGMS guidance – European Geriatric Medicine

Conteúdos relacionados:

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)

Estimativa da taxa de fatalidade da infecção (TFI) por SARS-CoV-2 por idade e status de comorbidade usando o rastreamento de anticorpos em doadores de sangue durante a epidemia de COVID-19 na Dinamarca – “A TFI foi baixa em pessoas com menos de 51 anos sem comorbidade durante as 2 ondas (TFI combinada = 3,36 por 100.000 infecções).”

22 Nov, 2021 | 09:35h

Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – The Journal of Infectious Diseases

 

Comentário no Twitter

 

M-A | Plasma convalescente não reduz a mortalidade na COVID-19.

22 Nov, 2021 | 09:34h

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials – BMC Infectious Diseases

Conteúdos relacionados:

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

Delta é a última “supervariante” da Covid?

22 Nov, 2021 | 09:32h

Is Delta the last Covid ‘super variant’? – The Guardian

Não, pessoas vacinadas não são “tão infecciosas” quanto pessoas não vacinadas caso venham a ter COVID.

22 Nov, 2021 | 09:31h

No, vaccinated people are not ‘just as infectious’ as unvaccinated people if they get COVID – The Conversation

Diretriz de Consenso | U.S. Multi-Society Task Force sobre câncer colorretal agora sugere que o rastreamento da doença comece aos 45 anos de idade.

22 Nov, 2021 | 09:30h

Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the U.S. Multi-Society Task Force on Colorectal Cancer – Gastroenterology

Comunicado de imprensa: US Multi-Society Task Force on colorectal cancer releases updated screening recommendations - American Gastroenterological Association

Conteúdos relacionados:

State of the Art Review: Screening and prevention of colorectal cancer.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

Estudo randomizado | Entre pacientes com transtorno bipolar ou depressão que sobreviveram a evento recente relacionado a suicídio, lítio como terapia adicional não foi efetivo na prevenção de desfechos repetidos relacionados a suicídio.

22 Nov, 2021 | 09:28h

Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder – JAMA Psychiatry (gratuito por tempo limitado)

Entrevista com o autor: Lithium for Suicide-Related Outcome Prevention in Veterans With Major Depression or Bipolar Disorder

Comentário: Lithium Added To Current Tx Fails to Reduce Suicide-Related Events in Veterans – Physician’s Weekly

 

Comentário no Twitter

 

M-A | Em pacientes com síndromes coronarianas agudas sem elevação do segmento ST, o pré-tratamento com inibidores de P2Y12 por via oral antes da angiografia foi associado com risco aumentado de sangramento, sem diferença nos desfechos cardiovasculares.

22 Nov, 2021 | 09:25h

Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis – JAMA Network Open

Comentário convidado: Pretreatment in the Setting of Non–ST-Elevated Acute Coronary Syndrome—When It Is Time to Change – JAMA Network Open

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.